- Home
- BTAI vs NDLS Comparison
BTAI vs NDLS Comparison
Compare BTAI & NDLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- NDLS
- Stock Information
- Founded
- BTAI 2017
- NDLS 1995
- Country
- BTAI United States
- NDLS United States
- Employees
- BTAI N/A
- NDLS N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- NDLS Restaurants
- Sector
- BTAI Health Care
- NDLS Consumer Discretionary
- Exchange
- BTAI Nasdaq
- NDLS Nasdaq
- Market Cap
- BTAI 28.7M
- NDLS 32.9M
- IPO Year
- BTAI 2018
- NDLS 2013
- Fundamental
- Price
- BTAI $0.36
- NDLS $0.69
- Analyst Decision
- BTAI Strong Buy
- NDLS Strong Buy
- Analyst Count
- BTAI 4
- NDLS 2
- Target Price
- BTAI $5.00
- NDLS $3.00
- AVG Volume (30 Days)
- BTAI 949.6K
- NDLS 177.9K
- Earning Date
- BTAI 11-14-2024
- NDLS 11-06-2024
- Dividend Yield
- BTAI N/A
- NDLS N/A
- EPS Growth
- BTAI N/A
- NDLS N/A
- EPS
- BTAI N/A
- NDLS N/A
- Revenue
- BTAI $2,276,000.00
- NDLS $495,817,000.00
- Revenue This Year
- BTAI $164.86
- NDLS N/A
- Revenue Next Year
- BTAI $69.74
- NDLS $0.14
- P/E Ratio
- BTAI N/A
- NDLS N/A
- Revenue Growth
- BTAI 83.25
- NDLS N/A
- 52 Week Low
- BTAI $0.35
- NDLS $0.60
- 52 Week High
- BTAI $4.17
- NDLS $3.50
- Technical
- Relative Strength Index (RSI)
- BTAI 32.49
- NDLS 42.72
- Support Level
- BTAI $0.35
- NDLS $0.67
- Resistance Level
- BTAI $0.52
- NDLS $0.74
- Average True Range (ATR)
- BTAI 0.06
- NDLS 0.06
- MACD
- BTAI -0.00
- NDLS 0.02
- Stochastic Oscillator
- BTAI 2.92
- NDLS 60.00
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About NDLS Noodles & Company
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.